Budget impact model made by Evidências - Kantar Health is one of the highlights of ISPOR Europe 2018

 Budget impact model made by Evidências - Kantar Health is one of the highlights of ISPOR Europe 2018

One of the posters that Evidências - Kantar Health attended the 21st European Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) highlighted in the TOP 10 ranking. The event was held in Barcelona, Spain from November 10th to 14th and is one of the most important channels of scientific dissemination on pharmacoeconomics and results research.

The study titled Budget impact model of subcutaneous trastuzumab compared with intravenous trastuzumab on the treatment of HER-2 positive breast cancer in the Brazilian Private Healthcare System is authored by the team of Evidências - Kantar Health in partnership with a global client.


The study

In metastatic breast cancer, trastuzumab was associated with docetaxel or paclitaxel in the first line and monotherapy in the second. For both, compared the replacement of intravenous trastuzumab with the subcutaneous. A survey of 28 carriers mapped rates, prices and reference tables used for reimbursement of drugs, materials, and procedures. A multidisciplinary team estimated resource use and direct medical costs were included, in addition to prices obtained from public sources. The time horizon was five years and the progressive incorporation of subcutaneous trastuzumab with 20% in the first year considered until reaching 100%. From this cut, it was estimated that 31,589 patients with breast cancer in the in the Brazilian private healthcare system in five years, with the progressive use of trastuzumab subcutaneous compared to intravenous, led to savings of 948.2 mBRL, 14.3 mBRL, 1.5 mBRL and 0.2 mBRL in the private healthcare system, for large, medium and small health care providers, respectively. Materials and support procedures with medical fees were the most sensitive parameters.



ISPOR is one of the most important scientific channels for dissemination of pharmacoeconomics and outcomes research. Besides being a public non-profit organization for educational and scientific purposes, the objective of ISPOR is promoting the science of pharmacoeconomics and the research results and facilitating the translation of this research into useful information for decision makers in the area of healthcare. The society has more than 6,500 members in 100 countries and 62 regional chapters with over 4,800 members. ISPOR promotes three annual meetings, conducted in North America, Europe, and Latin America or Asia.

The full study is available in the annex below.


Subscribe to our newsletter